Bank of America Corp., the second-largest U.S. bank by assets, allocates more than $250 million each year on GLP-1-based weight-loss drugs for its employees, Chief Executive Officer Brian Moynihan stated to CNBC. He said that four or five years prior, these costs were nonexistent, yet they signify...